Evercore ISI Group maintains Ralliant at Outperform, raises price target to $90 from $85
Evercore ISI Group maintained its Outperform rating on Ralliant and raised its price target to $90 from $85, implying a 25.7% upside from the Nov 4 close of $71.58. Recent analyst price targets for Ralliant range from $72 to $88.
How this was made

The 30-second read
Why it matters
The price target raise could attract speculative buying but overall market impact is modest.
Market read
Small but notable for traders focused on microcap biotech upgrades.
What to watch
Liquidity constraints and broader market risk for microcaps.
Background
Ralliant is a small-cap biotech whose recent analyst coverage is limited.
Market effects
Minor effect on biotech sector sentiment.
Limited to US microcap investors.
Low
Counterpoint
The upgrade may be premature given limited fundamentals.
Key entities
- Analyst FirmEvercore ISI Group
Provided the upgraded rating and new price target.
- CompanyRalliant
Biotech firm receiving the analyst upgrade.


